Lenvatinib mesylate
Lenvatinib mesylate is an orally bioavailable, multi-targeted tyrosine kinase inhibitor that potently suppresses VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. It is widely used in preclinical in vitro and in vivo studies for investigating angiogenesis, tumor growth, and metastasis in various cancer models.
Product Specifications
CAS Number
857890-39-2
Product Name Alternative
Vascular endothelial growth factor receptor, VEGFR, VEGFR1, VEGFR3, RET, SCFR, PDGFR, PDGFRα, PDGFRβ, Inhibitor, inhibit, Platelet-derived growth factor receptor, FGFR1, FGFR, Fibroblast growth factor receptor, E7080 (mesylate), E7080, E-7080, Lenvatinib, Lenvatinib mesylate, Lenvatinib Mesylate, CD117, c-Kit, cKit, cRET, E 7080
Field of Research
Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.03% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.82 mM) ; DMSO:32.67 mg/mL (62.47 mM)
Smiles
CS (O) (=O) =O.COc1cc2nccc (Oc3ccc (NC (=O) NC4CC4) c (Cl) c3) c2cc1C (N) =O
Molecular Formula
C22H23ClN4O7S
Molecular Weight
522.96
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
